OPKO Health shares gain momentum as the company offloads BioReference Health assets to Labcorp in a $722 million deal aimed at bolstering liquidity and streamlining operations.
OPKO Health is divesting select assets from its BioReference Health subsidiary to Labcorp in a transaction valued at over $722 million. This strategic move is expected to provide substantial cash proceeds, which will likely be utilized to strengthen the company's balance sheet and support its core biopharmaceutical operations.
OPKO will receive over $722 million in cash proceeds from the sale of select BioReference Health assets.
Labcorp is expanding its diagnostic footprint by acquiring select assets from BioReference Health, a subsidiary of OPKO Health. This acquisition, valued at over $722 million, aligns with Labcorp's strategy to scale its diagnostic capabilities and market presence.
Labcorp is acquiring select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health.
OPKO Health has entered a definitive agreement to divest select assets from its BioReference Health subsidiary to Labcorp. The transaction, valued at over $722 million, provides OPKO with a significant cash infusion to strengthen its balance sheet while allowing Labcorp to expand its diagnostic testing footprint.
The sale of select BioReference Health assets provides OPKO Health with over $722 million in cash, significantly improving the company's liquidity and balance sheet position.
Labcorp (Laboratory Corporation of America Holdings) is the purchaser of the select assets from OPKO Health's subsidiary, BioReference Health.